Selected Toxicities of Targeted Therapies: Presentation and Management

被引：7
|
作者：
Kollmannsberger, Christian [1 ]
Mitchell, Teresa [1 ]
机构：
[1] British Columbia Canc Agcy, Vancouver Canc Ctr, Div Med Oncol, Vancouver, BC V5Z 4E6, Canada
来源：
SEMINARS IN ONCOLOGY | 2013年 / 40卷 / 04期
关键词：
RENAL-CELL CARCINOMA; ENDOTHELIAL GROWTH-FACTOR; INTERFERON-ALPHA; FACTOR RECEPTOR; SUNITINIB; EFFICACY; HYPERTENSION; EVEROLIMUS; TEMSIROLIMUS; BEVACIZUMAB;
D O I：
10.1053/j.seminoncol.2013.05.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The introduction of targeted therapy has changed the landscape of metastatic renal cell carcinoma (mRCC) but has also brought challenges. One such challenge of treating this chronic disease is long-term therapy, which produces ongoing toxicity. Knowledge of the spectrum of toxicity from targeted therapy and appropriate and timely intervention is required to maintain adequate dosing required for optimal outcome. This article addresses some of the major toxicities of newer agents in RCC and discusses management strategies. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码：499 / 510
页数：12
相关论文
共 50 条
  • [41] Management of side effects of targeted therapies in renal cancer: iatrogenic side effects
    Massard, Christophe
    Patard, Jean-Jacques
    Hermine, Olivier
    Ravaud, Alain
    BULLETIN DU CANCER, 2011, 98 : S79 - S94
  • [42] Management of side effects of targeted therapies in renal cancer: cutaneous side effects
    Robert, Caroline
    Gimel, Pierre
    BULLETIN DU CANCER, 2011, 98 : S35 - S46
  • [43] Gastrointestinal toxicities from targeted therapies: measurement, duration and impact
    Bossi, Paolo
    Lucchesi, Maurizio
    Antonuzzo, Andrea
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2015, 9 (02) : 163 - 167
  • [44] Selecting Targeted Therapies for Patients With Renal Cell Carcinoma
    Plimack, Elizabeth R.
    Hudes, Gary R.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011, 9 (09): : 997 - 1007
  • [45] Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours
    Yim, Kein-Leong
    ENDOCRINE, 2011, 40 (02) : 181 - 186
  • [46] Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms
    Vijayvergia, Namrata
    Dasari, Arvind
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (12)
  • [47] Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma
    Seront, Emmanuel
    Machiels, Jean-Pascal
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2009, 4 (02) : 146 - 156
  • [48] Targeted therapies in the management of colorectal carcinoma: role of bevacizumab
    Puthillath, Ajithkumar
    Patel, Anush
    Fakih, Marwan G.
    ONCOTARGETS AND THERAPY, 2009, 2 : 1 - 15
  • [49] Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors
    Capdevila, Jaume
    Salazar, Ramon
    TARGETED ONCOLOGY, 2009, 4 (04) : 287 - 296
  • [50] Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma
    Pracht, Marc
    Berthold, Dominik
    SUCCESSES AND LIMITATIONS OF TARGETED CANCER THERAPY, 2014, 41 : 98 - 112
12345